重组人GUCY2C蛋白, His Tag

FITC-Labeled Human GUCY2C / Guanylyl cyclase C Protein, His Tag

分子别名（Synonym）

GUCY2C,GUC2C,STAR,STA receptor,hSTAR,GC-C

表达区间及表达系统（Source）

FITC-Labeled Human GUCY2C Protein, His Tag (GUC-HF2H9) is produced via conjugation of FITC to Human GUCY2C Protein, His Tag with a new generation site-specific technology under Star Staining labeling platform. Human GUCY2C Protein, His Tag is expressed from human 293 cells (HEK293). It contains AA Ser 24 - Gln 430 (Accession # P25092-1).

Predicted N-terminus: Ser 24

蛋白结构（Molecular Characterization）

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 62.3 kDa.

偶联（Conjugate）

FITC

Excitation source: 488 nm spectral line, argon-ion laser

Excitation Wavelength: 488 nm

Emission Wavelength: 535 nm

制剂（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储（Storage）

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

-20°C to -70°C for 12 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

背景介绍

GUCY2C (Guanylyl Cyclase C), also known as heat-stable enterotoxin receptor, is a type I transmembrane protein of the guanylate cyclase (gc) family that signal by producing cGMP. Guanylate cyclase C (GUCY2C) and its hormones guanylin and uroguanylin have recently emerged as one paracrine axis defending intestinal mucosal integrity against mutational, chemical, and inflammatory injury. GUCY2C murine CAR-T cells recognized and killed human colorectal cancer cells endogenously expressing GUCY2C. Thus, we have identified a human GUCY2C-specific CAR-T cell therapy approach that may be developed for the treatment of GUCY2C-expressing metastatic colorectal cancer.